MTNB Matinas Biopharma Holdings Inc.

1.56
+0.07  (+5%)
Previous Close 1.49
Open 1.49
Price To Book 7.43
Market Cap 253,874,827
Shares 162,740,274
Volume 6,658,308
Short Ratio 1.84
Av. Daily Volume 3,559,177
Stock charts supplied by TradingView

NewsSee all news

  1. Matinas BioPharma Announces Closing of Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing 

  2. Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing

  3. Matinas BioPharma Announces Proposed Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has

  4. Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

    BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group.

  5. Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has

Drug Information

Drug catalyst information is displayed when you hover over / tap on the stage bar graph.

Phase 2 trial initiation announced October 14, 2019.
MAT2203
Vulvovaginal candidiasis (VVC)
Phase 2 trial against Vascepa to commence 1Q 2020 with top-line data due 2H 2020.
MAT9001
Severe hypertriglyceridemia
Phase 2 trial to be initiated 2H 2019.
Cryptococcal meningitis
Cryptococcal meningitis

Latest News

  1. Matinas BioPharma Announces Closing of Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 14, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the closing 

  2. Matinas BioPharma Announces Pricing of Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 10, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced the pricing

  3. Matinas BioPharma Announces Proposed Public Offering of Common Stock

    BEDMINSTER, N.J., Jan. 09, 2020 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. ("Matinas BioPharma" or the "Company") -- (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that it has

  4. Matinas BioPharma Announces Feasibility Evaluation with Third Large Biopharmaceutical Company for the Formulation of Compounds Utilizing LNC Delivery Platform

    BEDMINSTER, N.J., Dec. 12, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), today announced that it has entered into a feasibility evaluation with Genentech, a member of the Roche Group.

  5. Matinas BioPharma to Present at the 31st Annual Piper Jaffray Healthcare Conference

    BEDMINSTER, N.J., Nov. 18, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, has

  6. Matinas BioPharma Reports Third Quarter 2019 Financial Results and Provides Corporate Update

    – Initiated pre-screening of patients for Phase 2 ENHANCE-IT study of MAT9001 against Vascepa®. Enrollment to commence Q1 2020, with topline data expected H2 2020 – – NIH-funded Phase 2 EnACT trial of MAT2203 in

  7. Matinas BioPharma to Webcast Conference Call Discussing Third Quarter 2019 Operational and Financial Results on November 13, 2019

    BEDMINSTER, N.J., Nov. 06, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, today announced that the Company will host a conference call and live

  8. Matinas BioPharma Initiates EnACT Study of MAT2203 (Oral Amphotericin B) for the Treatment of Fungal Cryptococcal Meningitis

    BEDMINSTER, N.J., Oct. 14, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has initiated its Phase 2 EnACT clinical

  9. Matinas BioPharma Receives Orphan Drug Designation From U.S. FDA for MAT2203 for the Treatment of Cryptococcosis

    BEDMINSTER, N.J., Oct. 07, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical-stage biopharmaceutical company, announced today that the U.S. Food and Drug Administration (FDA) has

  10. Matinas BioPharma to Present at the 2019 Cantor Global Healthcare Conference

    BEDMINSTER, N.J., Sept. 27, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will

  11. Matinas BioPharma Announces Pre-Screening of Patients to Determine Eligibility for Phase 2 ENHANCE-IT Study Against Vascepa®

    BEDMINSTER, N.J., Sept. 25, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that it has commenced pre-screening patients to

  12. Velan Launches Consent Solicitation to Reconstitute the Progenics Board With Its Five Highly-Qualified, Independent Director Nominees

    Believes its Five Completely Independent Nominees Would Bring Much-Needed Skill Sets and Drastically Improve the Board's Strategic Oversight and Corporate Governance Failings Expresses Disappointment with Current

  13. Matinas BioPharma to Present at the H.C. Wainwright 21st Annual Global Investment Conference

    BEDMINSTER, N.J., Aug. 28, 2019 (GLOBE NEWSWIRE) -- Matinas BioPharma Holdings, Inc. (NYSE AMER: MTNB), a clinical stage biopharmaceutical company, today announced that Jerome D. Jabbour, Chief Executive Officer, will